Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5HF
|
|||
| Former ID |
DNCL002837
|
|||
| Drug Name |
BI-135585
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H32N2O4
|
|||
| Canonical SMILES |
CC(C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CCC(OC3=O)(CC(C)(C)O)C4=CC=CC=C4
|
|||
| InChI |
1S/C28H32N2O4/c1-20(21-10-12-22(13-11-21)23-14-16-29(4)25(31)18-23)30-17-15-28(34-26(30)32,19-27(2,3)33)24-8-6-5-7-9-24/h5-14,16,18,20,33H,15,17,19H2,1-4H3/t20-,28-/m0/s1
|
|||
| InChIKey |
TXNPQZGSVXLGGP-MMTVBGGISA-N
|
|||
| CAS Number |
CAS 1114561-85-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) | Target Info | Modulator | [2] |
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolism of xenobiotics by cytochrome P450 | ||||
| Metabolic pathways | ||||
| Chemical carcinogenesis | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| FSH Signaling Pathway | ||||
| Pathwhiz Pathway | Steroidogenesis | |||
| Reactome | Glucocorticoid biosynthesis | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01282970) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes. U.S. National Institutes of Health. | |||
| REF 2 | New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.